MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2018.01.075

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2018

Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.

Hillen Uwe, Leiter Ulrike, Haase Sylvie, Kaufmann Roland, Becker Jürgen, Gutzmer Ralf, Terheyden Patrick, Krause-Bergmann Albrecht, Schulze Hans-Joachim, Hassel Jessica, Lahner Nina, Wollina Uwe, Ziller Fabian, Utikal Jochen, Hafner Christine, Ulrich Jens, Machens Hans-Günther, Weishaupt Carsten, Hauschild Axel, Mohr Peter, Pföhler Claudia, Maurer Jan, Wolff Patrick, Windemuth-Kieselbach Christine, Schadendorf Dirk, Livingstone Elisabeth, Dermatologic Cooperative Oncology Group (DeCOG)

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Advanced cutaneous squamous cell carcinoma (aSCC) is an area of unmet medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor received FDA breakthrough therapy designation. The aim of the study was to describe the clinical course, therapeutic management and prognosis of aSCC under real-life conditions.

PATIENTS AND

METHODS

In a retrospective study performed in 24 German and Austrian hospitals and doctor's offices, patient and tumour characteristics of patients diagnosed with aSCC between January 1, 2010 and December 31, 2011 and their disease course was documented. Advanced SCC comprised either locally advanced SCCs (laSCC) or metastatic SCCs (mSCC) with any kind of metastatic spread.

RESULTS

Data of 190 patients with aSCC were analysed. Median age at time of diagnosis of aSCC was 78 years. LaSCC was diagnosed in 76 patients (40%), 114 patients (60%) had mSCC. Once diagnosed with laSCC, most patients (59%) did not receive any therapy, whereas in 92% of mSCC patients at least one type of therapy was performed. Only 32 patients (29 mSCC, 3 laSCC) received systemic antitumour therapies, mostly EGFR inhibitor-based regimens. Mean duration of response was short (17-months laSCC patients, 3-months mSCC patients). Only 2 patients achieved a complete response, 27% had a partial response, 43% disease stabilisation. At diagnosis of aSCC, ECOG status was 0-1 in most patients. Non-malignant comorbidities influenced the decision on SCC-specific therapy in 39 patients (21%).

CONCLUSIONS

Our data show the high medical need for efficient and tolerable antitumour therapies and demonstrate that despite older age and comorbidities, most patients can be expected to be fit for treatment. This study provides a historical context for emerging aSCC treatments.

Для цитирования: Hillen Uwe, Leiter Ulrike, Haase Sylvie, Kaufmann Roland, Becker Jürgen, Gutzmer Ralf, Terheyden Patrick, Krause-Bergmann Albrecht, Schulze Hans-Joachim, Hassel Jessica, Lahner Nina, Wollina Uwe, Ziller Fabian, Utikal Jochen, Hafner Christine, Ulrich Jens, Machens Hans-Günther, Weishaupt Carsten, Hauschild Axel, Mohr Peter, Pföhler Claudia, Maurer Jan, Wolff Patrick, Windemuth-Kieselbach Christine, Schadendorf Dirk, Livingstone Elisabeth, Dermatologic Cooperative Oncology Group (DeCOG). Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.. European journal of cancer (Oxford, England : 1990). 2018. DOI: 10.1016/j.ejca.2018.01.075.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.